RxDoctor Payments Data

Bhumi Kinariwala, MD

Internal Medicine · Allentown, PANPI 1548798143

Payments from drug & device makers

$1,672in general payments, 2019–2025

Across 50 payments — averaging $33.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$481
  • Bausch & Lomb Americas Inc.$239
  • Sun Pharmaceutical Industries Inc.$191
  • AbbVie$125
  • Johnson & Johnson Surgical Vision, Inc.$120
  • Tarsus Pharmaceuticals, Inc.$71
  • plus $445 from 9 others

What the payments were for

  • Food & beverage$1,65499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,672 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,796
Medicare patients
87
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast123$153,769
MieboPerfluorohexyloctane/Pf60$49,181
RestasisCyclosporine49$38,008
Cyclosporine28$15,328
CequaCyclosporine14$14,001
TobradexTobramycin/Dexamethasone12$4,100
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,800
Prednisolone Acetate29$1,198
Latanoprost35$656
Brimonidine Tartrate25$580
ValacyclovirValacyclovir Hcl23$543
MoxifloxacinMoxifloxacin Hcl14$519
Ciprofloxacin Hcl33$508
Doxycycline Hyclate24$466
ErythromycinErythromycin Base23$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$239$202,950183 claims
AbbVieRestasis$125$38,00849 claims
Sun Pharmaceutical Industries Inc.Cequa$191$14,00114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →